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Abstract
Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with tumor aggressiveness and poor
prognosis in breast cancer. With the availability of therapeutic antibodies against HER2, great strides have been made in the
clinical management of HER2 overexpressing breast cancer. However, de novo and acquired resistance to these antibodies
presents a serious limitation to successful HER2 targeting treatment. The identification of novel epitopes of HER2 that can
be used for functional/region-specific blockade could represent a central step in the development of new clinically relevant
anti-HER2 antibodies. In the present study, we present a novel computational approach as an auxiliary tool for identification
of novel HER2 epitopes. We hypothesized that the structurally and linearly evolutionarily conserved motifs of the
extracellular domain of HER2 (ECD HER2) contain potential druggable epitopes/targets. We employed the PROSITE Scan to
detect structurally conserved motifs and PRINTS to search for linearly conserved motifs of ECD HER2. We found that the
epitopes recognized by trastuzumab and pertuzumab are located in the predicted conserved motifs of ECD HER2,
supporting our initial hypothesis. Considering that structurally and linearly conserved motifs can provide functional specific
configurations, we propose that by comparing the two types of conserved motifs, additional druggable epitopes/targets in
the ECD HER2 protein can be identified, which can be further modified for potential therapeutic application. Thus, this novel
computational process for predicting or searching for potential epitopes or key target sites may contribute to epitope-
based vaccine and function-selected drug design, especially when x-ray crystal structure protein data is not available.
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Introduction
Human epidermal growth factor receptor 2 (HER2) is one of
four members of the EGF receptor family of receptor tyrosine
kinases that mediate cell proliferation, differentiation and survival
[1]. Overexpression of HER2, resulting from amplification of the
ErbB2 gene, is observed in approximately 20% of breast cancers,
and amplification of HER2 significantly correlates with increased
disease aggressiveness and thereby with poor patient outcome
[2,3,4,5,6]. Overexpression of HER2 can be detected in the early
stages of breast cancer, and it is maintained in the progression to
metastatic disease [7,8], indicating that HER2 has an important
effect on breast cancer progression. As a result, HER2 has become
a critical therapeutic target in the treatment of breast cancer
patients.
Trastuzumab, a monoclonal antibody directed against the
extracellular domain of HER2, which consists of four domains
(domain I, II, III and IV) [9], is currently the first choice of
treatment for HER2-positive breast cancer patients, as it improves
overall survival and reduces the risk of disease recurrence when
administered in combination with chemotherapy (for review see
[10]). Nevertheless, not all HER2 positive patients benefit from
Trastuzumab treatment [11] and around 15% of breast cancer
patients relapse after an initial response to trastuzumab-based
therapy, suggesting that de novo or acquired resistance to
trastuzumab has developed [12]. Thus, additional therapeutic
agents are necessary in the treatment of HER2-positive breast
cancer patients, with the aim of improving survival.
Pertuzumab is another humanized monoclonal antibody that
binds to the extracellular domain II of HER2, the dimerization
arm [13], thereby blocking signaling transduction that results from
dimerization with other members of the EGFR family [14].
Although pertuzumab had low clinical efficacy when used alone, it
has an excellent effect in HER2-positive breast cancer patients
when used in combination with trastuzumab [15,16,17]. Pertuzu-
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mab administrated in combination with trastuzumab and
docetaxel significantly prolongs the progression-free survival
without increased cardiac toxic side effects in metastatic breast
cancer patients [18,19]. These data suggest that an additive or
perhaps synergistic effect can be achieved using several antibodies
directed against different epitopes of the same protein (HER2)
[19].
Another therapeutic strategy to block HER2 makes use of small
molecule tyrosine kinase inhibitors (TKIs), such as the dual
EGFR/HER2 TKI lapatinib [20,21]. Unfortunately, as it is the
case for other molecular targeted therapies, the clinical responses
to lapatinib tend to be short-lived. However, several lines of
evidence suggest continued dependence of HER2+ breast cancers
on HER2 signaling network after progression on anti-HER2
therapy (reviewed in [22]), providing a rationale for multilayered
HER2 blockade. Therefore, searching for additional epitopes/
targets of HER2 is needed to broaden clinical selection and
improve the efficacy of anti-HER2 treatment. Currently, the use of
three-dimensional (3D) structural data combined with some
experimental approaches such as pepscan, phage display, or
mutagenesis scanning, are the gold standard of epitope-based
vaccine design [23,24]. But 3D data are not available for all
proteins, and experimental approaches are expensive and time-
demanding techniques. Thus, computational processes that could
function as a compensational approach to predictably identify
some desirable epitopes or functional targets for rational vaccine
or drug design are badly needed.
In the present study, we report a novel computational process
used to predict functional motifs of HER2, which matched very
well with epitopes of trastuzumab and pertuzumab (HER2’s
antibodies).
Materials and Methods
Data collection and protein BLAST (basic local alignment
search tool)
The human HER2 amino acid sequence with accession number
P04626 was compared to the UNIPROT database using BLAST
via the web service (http://www.uniprot.org/) with default setting.
Structural conserved motifs scanning in PROSITE
database
According to the domain organization of the ErbB family, the
extracellular domain region of HER2 has,620 residues [25]. The
human extracellular domain of HER2 (1-620) amino sequence was
uploaded in the PROSITE Scan online service (http://prosite.
expasy.org/scanprosite/). The databases used for structurally
conserved motifs scanning included UniProtKB/Swiss-Prot, splice
variants and UniProtKB/TrEMBL databases. The searching
results with low level scores were also allowed to show in the
output. The other parameters used the default setting.
Searching for fingerprints in the PRINTS database
The amino sequence of the extracellular domain of HER2 (ECD
HER2) was aligned for fingerprints in web service (http://www.bioinf.
man.ac.uk/cgi-bin/dbbrowser/fingerPRINTScan/FPScan_fam.cgi )
with default settings.
Comparison of structurally conserved motifs with the
epitopes of HER2’s antibodies based on the crystal 3D
structure
The crystal structure of the extracellular domain of the human
HER2 complexed with trastuzumab Fab (PDB ID: 1N8Z) and the
structure of HER2-pertuzumab complex (PDB ID: 1S78) were
obtained from NCBI (http://www.ncbi.nlm.nih.gov/structure/
?term=HER2). Using Cn3D software, the structurally conserved
fragments of ECD HER2 were superposed and labeled on the two
crystal structures. Furthermore, as supplementary reference to our
prediction, FoldX (http://foldx.crg.es/) were introduced with in
silico mutagenesis ’repair module’, which allowed to predict the
amino acids involved in the binding of HER2 to the antibodies by
alanine mutation based on ’force field’ statistical considerations
[26].
Results
The HER2 amino acid sequence was highly conserved in
mammals
We hypothesized that functional structure motifs could be
conserved and maintained during evolution. In order to determine
the level of homology in the HER2 amino acid sequence among
mammals, available orthologs of HER2 were searched by BLAST
in the UniProt database. The result showed that the HER2 protein
sequence indeed was highly homologous across species with over
80% similarity in mammals, including horse (Equus caballus), pig
(Sus scrofa), mouse (Mus musculus), rat (Rattus norvegicus), and
cow (Bos taurus) (Table 1). This indicated that some meaningful
sequences/structures of ECD HER2 protein existed among these
conserved amino acid sequences.
The ECD HER2 protein sequence contained three
evolutionally conserved structural motifs
To determine the structurally conserved motifs in the ECD
HER2 protein, the protein sequence from M1 to E620 was
uploaded in Prosite ExPASy. We obtained three hits (Table 2).
The first hit, Fragment 1 (F1), was predicted as a type of Sushi
domain by the presence of four conserved cysteine residues (C246-
C293 and C277-C309), forming two disulfide bounds [27], which
covered amino acid residues from L244 to K311 according to the
PDB sequence number.
The second hit, Fragment 2 (F2), was predicted as a NHL
domain, defined by amino acid homological presenting in three
proteins: NCL-1, HT2A, and LIN-41[28], which was located from
N549 to E558 (PDB sequence number). Finally, the third hit,
Fragment 3 (F3), was predicted as a degenerated zinc finger
THAP-type domain (C2H2) [29,30], which embraced 29 amino
residues from D570 to E598 (PDB sequence number) (Table 2).
The zinc finger HTAP degenerate domain mapped to the N-
terminal location of a sequence-specific DNA-binding factor
[31,32].
Three structurally conserved fragments are located in
functional domains of ECD HER2
In order to explore the superposition of those structurally
conserved fragments with functional domains of ECD HER2, the
predicted fragments were superposed on the crystal structure of
ECD HER2 (Figure 1) [33]. F1 (L244-K311) was completely
located at center of domain II (G200-R329), which formed the
exposed dimerization arm of HER2, suggesting that the predicted
fragment F1 involved in HER2 dimerization and hereby could
affect the activation of HER2. F2 (N549-E558) and F3 (D570-
E598) were located at domain IV (W499-N607) which was the
arm extending to domain II and further mediating the activation
of HER2. Trastuzumab worked well in clinic via its interaction
with this domain [33]. The results indicated that these two
predicted fragments are matched with HER2’s functional domains
Evolutionary Conserved Motifs of HER2 Contain Novel Druggable Epitopes
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Table 1. The identity of human HER2 protein in the UniPort database.
Enter accession
number Organism Protein names Length Identity
P04626 Homo sapiens (Human) Receptor tyrosine-protein kinase erbB-2 1255 100%
G3QPD2 Gorilla gorilla gorilla (Lowland gorilla) Uncharacterized protein 1258 99%
K7DJM0 Pan troglodytes (Chimpanzee) V-erb-b2 erythroblastic leukemia viral oncogene
homolog 2, neuro/glioblastoma derived oncogene
homolog (Avian)
1255 99%
H2QCV1 Pan troglodytes (Chimpanzee) Uncharacterized protein 1247 99%
G1QK40 Nomascus leucogenys (Hylobates
leucogenys)
Uncharacterized protein 1255 99%
P04626-4 Homo sapiens (Human) Isoform 4 of Receptor tyrosine-protein kinase erbB-2 1240 99%
I0FM22 Macaca mulatta (Rhesus macaque) Receptor tyrosine-protein kinase erbB-2 isoform a 1255 98%
G7NI22 Macaca mulatta (Rhesus macaque) Receptor tyrosine-protein kinase erbB-2 1255 98%
P04626-5 Homo sapiens (Human) Isoform 5 of Receptor tyrosine-protein kinase erbB-2 1225 100%
F6WAF2 Callithrix jacchus (White-tufted-ear
marmoset)
Receptor tyrosine-protein kinase erbB-2 isoform a
(Uncharacterized protein)
1255 96%
G7PUM4 Macaca fascicularis
(Cynomolgus monkey)
Receptor tyrosine-protein kinase erbB-2 1231 98%
H2NU95 Pongo abelii (Pongo pygmaeus abelii) Uncharacterized protein 1256 97%
F7CBG7 Callithrix jacchus (White-tufted-ear
marmoset)
Uncharacterized protein 1239 96%
F6UJQ9 Callithrix jacchus (White-tufted-ear
marmoset)
Uncharacterized protein 1225 97%
F6VNY4 Equus caballus (Horse) Uncharacterized protein 1258 94%
Q49LT4 Felis catus (Cat) (Felis silvestris catus) Epidermal growth factor receptor type 2 1260 94%
F1PIQ9 Canis familiaris (Dog)
(Canis lupus familiaris
Receptor tyrosine-protein kinase erbB-2 1260 93%
H0X3G4 Otolemur garnettii
(Garnett’s greater bushbaby)
Uncharacterized protein 1256 93%
H9BB15 Felis catus (Cat) (Felis silvestris catus) Erb2 1260 93%
G1SZL0 Oryctolagus cuniculus (Rabbit) Uncharacterized protein 1255 93%
M3WCC2 Felis catus (Cat) (Felis silvestris catus) Uncharacterized protein 1260 93%
H9BNW8 Ursus americanus (Euarctos americanus) V-erb-b2 erythroblastic leukemia viral
oncogene-like protein 2
1260 92%
G1LTV6 Ailuropoda melanoleuca (Giant panda) Uncharacterized protein 1263 92%
O18735 Canis familiaris (Dog)
(Canis lupus familiaris)
Receptor tyrosine-protein kinase erbB-2
(EC 2.7.10.1) (Proto-oncogene c-ErbB-2)
(p185erbB2) (CD antigen CD340)
1259 92%
I3M2X8 Spermophilus tridecemlineatus
(Ictidomys tridecemlineatus)
Uncharacterized protein 1259 93%
M3YU62 Mustela putorius furo (Mustela furo) Uncharacterized protein 1260 92%
F1MCQ7 Bos taurus (Bovine) Uncharacterized protein 1257 92%
W8FW17 Tupaia chinensis (Chinese tree shrew) ERBB2 1255 92%
A8WED5 Canis familiaris (Dog)
(Canis lupus familiaris)
HER-2 1242 93%
M3X794 Felis catus (Cat) (Felis silvestris catus) Uncharacterized protein 1260 92%
D2I2F8 Ailuropoda melanoleuca (Giant panda) Putative uncharacterized protein 1236 92%
G3SLF2 Loxodonta africana (African elephant) Uncharacterized protein 1257 90%
K7GS43 Sus scrofa (Pig) Uncharacterized protein 1231 91%
S7MLI8 Myotis brandtii (Brandt’s bat) Receptor tyrosine-protein kinase erbB-2 1227 91%
G3H5Y0 Cricetulus griseus (Cricetulus barabensis
griseus)
Receptor tyrosine-protein kinase erbB-2 1256 89%
S9YT31 Camelus ferus (Wild Bactrian camel) Receptor tyrosine-protein kinase erbB-2 1253 90%
F1RWM5 Sus scrofa (Pig) Uncharacterized protein 1234 88%
Q8K3F9 Rattus norvegicus (Rat) Neu protooncoprotein 1259 88%
F1LRR9 Rattus norvegicus (Rat) Receptor tyrosine-protein kinase erbB-2 1257 88%
Evolutionary Conserved Motifs of HER2 Contain Novel Druggable Epitopes
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e106448
and probably they were critical sites for HER2’s activation. (To
keep consistency with the crystal structure study [33], we used the
PDB residues number here, rather than the sequential residues
number of HER2.)
The structurally conserved fragments matched well with
epitopes of HER2 antibodies
To investigate whether the predicted structurally conserved
motifs/fragments could be key regions for the biological function(s)
of HER2, they were compared with epitopes of HER2 antibodies
based on the HER2: trastuzumab [33]/HER2: pertuzumab [14]
co-crystal structures, respectively. The result showed that the
conserved F1 did not locate in the interaction surface with
trastuzumab, whereas the F2 and F3 were involved in the interface
of trastuzumab binding (Figure 2A). According to Cho et al., three
loops in the domain IV of HER2 are involved in the HER2-
Trastuzumab binding surface [33] (Figure 2). We found the two
residues of F2 P557 and E558 were located in loop 1 (P557-D561).
The four residues of F3 D570, P571, P572 and F573 were
positioned in loop 2 (D570-F573), and the residues of F3 K593,
F594, P595, D596, E597 and E598 were found in loop 3 (K593-
P603) (Figure 2B). The results showed the predicted F2 and F3
partly consisted of the epitope of trastuzumab, implying the
predicted F2 and F3 probably are the pivotal regions for HER2’s
activation.
The structural conserved F1 was completely embedded in the
center of domain II (in blue, Figure 3A), which has been revealed
as the interface with pertuzumab [14]. Furthermore, we found that
the directly interacted residues of HER2 with pertuzumab, H245,
Y252, F257, K311 and H296, and important residues of HER2,
H245, V286, S288, L295, H296 and K311, for affinity with
pertuzumab [14] were located in the predicted conserved F1
(Figure 3B, showed in dark green). This result suggested that the
predicted conserved F1 contained pertuzumab’s epitopes.
All these structural comparisons results between the predicted
conserved fragments and epitopes of HER2’s antibodies implied
that the structurally/functionally conserved fragments of HER2
probably contain more potentially powerful epitopes/target sites.
The ECD HER2 protein sequence contained some
conserved fingerprints
For purpose of combination of linear feature and structural
characterization of epitopes to reduce the prediction error, the
PRINTS database, another deterministic pattern, was introduced.
And then, 9 top fingerprints were significantly screened from the
ECD HER2 sequence with p-value,0.01 (Table 3). Among them,
the fingerprints ANATRNSFRASE 280, BACEL 290, and
TRANSYNTHGLU 316 overlapped with F1; the fingerprints
4FE4SFRDOXIN 577 partly overlapped with F2; the fingerprints
ALPHATUBULIN 600 and 4FE4SFRDOXIN 595 overlapped
with F3 (The position number is consistent with ECD HER2
amino acid number).
Some of both linear and structural conserved regions
were beyond the epitopes of HER2’s antibodies
To further explore the match between the linear and structural
conserved regions and epitopes of HER2’s antibodies (trastuzu-
mab and pertuzumab), they were compared. Some linear and
Table 1. Cont.
Enter accession
number Organism Protein names Length Identity
P06494 Rattus norvegicus (Rat) Receptor tyrosine-protein kinase erbB-2 1257 88%
W5PQJ8 Ovis aries (Sheep) Uncharacterized protein 1251 89%
Q60553 Mesocricetus auratus (Golden hamster) Receptor tyrosine-protein kinase erbB-2 1254 88%
P70424 Mus musculus (Mouse) Receptor tyrosine-protein kinase erbB-2 1256 88%
H0V6A0 Cavia porcellus (Guinea pig) Uncharacterized protein 1236 88%
J3QLU9 Homo sapiens (Human) Receptor tyrosine-protein kinase erbB-2 1055 99%
G1PRB8 Sarcophilus harrisii (Sarcophilus laniarius) Uncharacterized protein 1244 85%
G3WQQ2 Sarcophilus harrisii (Sarcophilus laniarius) Uncharacterized protein 1255 81%
F7C962 Monodelphis domestica (Gray short-tailed
opossum)
Uncharacterized protein 1257 80%
The table only shows resemblance to HER2 higher than 80%.
doi:10.1371/journal.pone.0106448.t001
Figure 1. The location of the three structurally conserved
motifs (F1, F2 and F3) on ECD HER2 crystal structure. Purple:
ECD HER2 receptor; Yellow: structurally conserved motifs (F1, F2 and
F3). N(C) and C(C) are ECD HER2’s N-terminal and C-terminal,
respectively.
doi:10.1371/journal.pone.0106448.g001
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structural conserved overlapped regions, including fingerprints
ALPHATUBULIN 600, ANTRNSFRASE 280, 4FE4SRDOXIN
595, BACE1 290 and TRNASYNTHGLU 316, did not present in
the interface of HER2:antibodies (Table 3. shaded fingerprints).
The result showed that the predicted structurally conserved
fragments contained some linearly conserved segments, suggesting
that those segments could be other efficient epitopes or drug target
sits. In order to evaluate the effect of those conserved motifs listed
in Table 3 on binding energies to pertuzumab and Fab
trasutumab, FoldX was introduced as a supplementary reference.
The result showed that some amino acids in the overlapped
regions of structurally and linearly conserved motifs were
predictively involved in the interaction with trastuzumab and
pertuzumab (Table 3), implying our prediction performance was
reliable.
Discussion
Great achievements have been obtained with antibody-based
therapies in the treatment of cancer [34]. Trastuzumab and
pertuzumab, two antibodies targeting the HER2 protein, are good
examples of antibody-based therapies. Clinical studies have shown
that these two monoclonal antibodies, which are directed against
different epitopes of HER2, display an additive/synergistic anti-
tumor effect when they are used in combination with docetaxel in
the treatment of metastatic breast cancer, even though some
patients developed resistance [15,16,19]. Hence, it is conceivable
that using several antibodies toward the same molecular target
results in an additive/synergistic effect, since the antibodies are
immunologically generated towards different parts of the antigen.
Therefore, more efficient antibodies against HER2 could provide
more options for treatment and greater benefits for HER2-positive
breast cancer patient than those presently in use.
The identification of the most efficient epitopes/target sites, as
the first step for epitope-based vaccine/drug design, is still an
unsolved problem. In the present study, we hypothesized that
evolutionary structurally conserved fragments of the ECD of
HER2 contain efficient druggable epitopes/targets.
We used the PROSITE database that can detect biologically
meaningful inter-domains, based on manually derived alignments
and extensive manually curated documentation [35], to predict
structurally conserved motifs. We also introduced the PRINTs
database which is a compendium of protein motifs with a series of
conserved regions of aligned sequences, since the linear segment is
another essential part of protein epitopes [36]. We found that all
predicted fragments were located in the important dimerization
arms regions of HER2: within domain II and IV. Comparing the
structurally conserved fragments of HER2 with epitopes of
trastuzumab and pertuzumab, respectively, we further found that
the predicted fragments were involved in the formation of epitopes
for trastuzumab and pertuzumab, which are the most efficient
known antibodies against HER2. Thus, our results showed that
the evolutionary structurally conserved fragments of HER2
contain novel epitopes/targets, not being targeted by trastuzumab
or pertuzumab, which strongly supports our hypothesis.
Furthermore, considering that the linear conserved motifs most
probably have a meaningful role in the formation of druggable
epitopes, we combined the two kinds of motifs and compared the
results generated. Some of these segments were not presented in
the epitopes of trastuzumab and pertuzumab, but included in the
structurally conserved fragments. The result implies that these
segments could be potential new epitopes/targets of ECD HER2
for peptide-based vaccine and drug design. Hence, this novel
computational process provides a new complementary approach
for efficiently selecting critical regions/sites as epitope for drug
targeting.
Numerous studies have shown that HER2 is involved in many
fundamental cellular processes, including cell migration, cell
survival and cell proliferation and differentiation (for review [1]),
suggesting that the basal function of HER2 is probably shared in
mammals. Indeed, our results confirmed that the homology of
HER2 amino acid sequence is very high in mammal species with
over 80% similarity. Thus, it is reasonable to suggest that some
similar functional inter-structures exist in the HER2 protein.
Three-conserved inter-structure motifs of ECD HER2 (named as
F1, F2 and F3) were identified as best hits using the PROSITE
Scan. The first two, F1 and F2, corresponding to the Sushi and
NHL domains in the ECD of HER2, respectively, are linked to
protein-protein interaction, protein-binding modules and cell
adhesion, all of which are coherent with the function of HER2,
a growth factor receptor protein [37,38,39,40,41].
However, the third domain, F3, was predicted as a degenerated
zinc finger HTAP domain, which has DNA-binding capability. It
is rather intriguing that the trans-membrane part of HER2 should
contain a DNA-binding domain, even if HER2 reportedly can
function as a transcriptional regulator [42]. Studies have
demonstrated that HER2 is involved in COX2
[43], and ribosomal RNA gene [44] transcriptional regulation
and HER2 can be located to the nucleus, where transcriptional
activity takes place reasonably [42]. In addition, a truncated
HER2 has also been reported to be located to nucleus and to
contribute to acquired resistance to HER2 kinase inhibitors
[45,46]. Taken as a whole these lines of evidence suggest that a
HER2 may function as a transcriptional regulator, in which case a
DNA-binding domain is not a remarkable finding.
We found that all identified fragments, based on their predicted
structural features, can be rationalized to match the activation of
HER2. Hence, this prediction approach probably is a believable
Table 2. The structurally conserved motifs of ECD HER2 detected by PROSITE Scan.
Predicted
Conserved motifs Amino Acid Residues Predicted domain (condition) Contact region
F1 (L244-K311; PDB
sequence number.)
LHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNY-
LSTDVGSCTLVCPLHNQEVTAEDGTQRCEK
Sushi (Disulfide 246C-x-293C
and 277C-x-309C)
Heterodimerization region and
Pertuzumab binding region.
F2 (N549-E558; PDB
sequence number.)
NGSVTCFGPE NHL Trastuzumab interacting region.
F3 (D570-E598; PDB
sequence number.)
DPPFCVARCPSGVKPDLSYMPIWKFPDEE ZF-THAP type, degenerate Trastuzumab interacting region.
The amino acids in bold present involved residues in epitopes of antibodies: trastuzumab and pertuzumab.
doi:10.1371/journal.pone.0106448.t002
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method for drug design, especially when one selects a protein or
activity of a protein to inhibit.
To add bio-function assessment to the predictive model, in the
present study, the correspondence between localization of
predicted fragments and HER2’s functional domains was studied
using co-crystal structure of ECD HER2: antibody.
The X-ray crystal structure of ECD HER2 has revealed that the
domain II of HER2, plays a key role in the activation of the
receptor, through which contacting and forming dimerization with
other ErbB family members [33,47]. According to our hypothesis,
some of evolutionally conserved fragments should be included in
domain II of HER2. Indeed, F1, as predicted as Sushi domain,
located in the center of domain II and completely overlapped with
interaction surface with pertuzumab [14]. Furthermore, Franklin
et al. revealed by a crystallographic study that the residues H245,
Y252, F257, H296 and K311 interact with pertuzumab directly,
and the residues H245, H296, K311, V286, S288 and L295
significantly mediated the affinity of HER2 to pertuzumab.
Figure 2. Comparison of structurally conserved motifs of ECD HER2 with the epitope of trastuzumab. A: The location of F1, F2 and F3 in
the tube worm representation of the HER2-trastuzumab complex. HER2 is colored dark brown and trastuzumab is in chain form: light chain in bright
purple and heavy chain in blue. The structurally conserved motifs (F1, F2 and F3) are highlighted in yellow. B: Enlarged view of binding interface
between ECD HER2 and trastuzumab. Trastuzumab is shown in grey, with a space-fill protein backbone and side chains style. The numbers indicted in
the figure show the three loop regions (highlighted in yellow) mediating the interaction with trastuzumab. F2 is shown in light green and F3 is in
bright purple. The overlapped residues between F2, F3 and interaction loops are P557 and E558 (F2, on loop 1 (P557-D561)), D570, P571, P572 and
F573 (F3, on loop 2 (D570-F573)), K593, F594, P595, D596, E597 and E598 (F3, on loop 3 (K593-P603)). According to the crystal structure of HER2-
trastuzumab complex [33], there are eight residues invisible in the F3 region. The numbers shown in the figure are consistent with PDB data rather
than sequential numbering for HER2 residues.
doi:10.1371/journal.pone.0106448.g002
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Without exception, we also found that all these pivotal residues
located in the predicted F1, as expected. This further confirms that
the structurally conserved motif F1 probably has more efficient,
potential epitopes/targets.
Results from X-ray structure analysis have shown that domain
IV of HER2 is another important domain for activation of HER2,
being involved in receptor-receptor contact [48,49], suggesting
that the domain IV should contain a receptor-receptor contacting
structure. Our prediction showed that a NHL structure in F2,
which has been proposed to be a protein-protein interaction
structure [39,41], exists in domain IV. Furthermore, the X-ray
crystal structure of the ECD HER2 complex with trastuzumab has
also revealed that domain IV of HER2 is the domain of epitope of
trastuzumab, by its’ loop 1 (P557-D561), loop 2 (D570-F573), and
loop 3 (K593-P603) to contact trastuzumab [33]. Similarity, our
predicted fragments F2 and F3 partly formed the epitope of
trastuzumab, which meet our expectations.
Since the linear peptides are the basis of forming epitopes, we
introduced the PRINTScan tool to scan the linear conserved
segment and compared these with structurally conserved motifs.
Figure 3. Comparison of structurally conserved motifs of ECD HER2 with the epitope of pertuzumab Fab. A: The location of F1 in the
tube worm representation of the HER2-pertuzumab complex. According to Franklin, M.C. et al. [14], ECD HER2 is colored according to domain:
domain I in pink, domain II in blue, domain III in dark purple and domain IV in grey. Pertuzumab is shown as a chain: light chain in green and heavy
chain in dark grey. The highlighted in yellow shows the location of structurally conserved F1. B: The enlarged view shows the binding interface
between ECD HER2 and pertuzumab. Domain II is shown in blue, and the F1 is shown as a tube worm with wire side-chains in dark green. The
residues involving in the interaction with pertuzumab [14] are highlighted in yellow. The numbers shown in the figure are consistent with PDB data
rather than sequential numbering for HER2 residues.
doi:10.1371/journal.pone.0106448.g003
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We found that some fingerprints also appeared in the rest residues
of the structurally conserved motifs (highlighted in Table 2). These
results indicate that the overlapped regions in structurally and
linearly conserved motifs could be potentially efficient epitopes/
targets for a new vaccine or drug design.
By and large, one can distinguish three main mechanism of
trastuzumab resistance: (1) functional bypass of blockade by either
up-regulation of downstream signaling or equivalent alternate
pathways, (2) failure to elicit immune-mediated killing of tumor
cells, and (3) hindrance of antibody binding to HER2. With
respect to the latter, our study may provide cues for novel
molecular mechanisms of resistance by pinpointing important
biological epitopes of ECD HER2. Conversely, the approach
presented here may provide the means to identify potentially
druggable epitopes/targets that can bypass known impediments to
antibody binding to HER2, such as expression of a constitutively
active, truncated form of HER2 that lacks the ECD, and
consequently the binding site of trastuzumab, or masking of
trastuzumab cognate epitopes by steric hindrance of HER2 by cell
surface proteins [45,50,51].
In conclusion, by comparing the structurally conserved motifs of
ECD HER2 protein with epitopes of trastuzumab and pertuzu-
mab, we confirmed our hypothesis that evolutionally structural
conserved motifs of the ECD HER2 protein contain potentially
druggable epitopes/targets. Furthermore, on the basis of a
comparison between the structurally conserved motifs and the
linearly conserved motifs, we proposed that some segments being
potentially more important biological epitopes of ECD HER2 can
be further modified for potential therapeutic application. In the
present study, we also provide a novel procedure to predict or
search for potential epitopes or key target sites in proteins, which
may contribute to the design of epitope-based vaccines and drugs.
In particular, when there is no X-ray crystal structure available, it
is easy to narrow the searching region by means of this process,
sharply reducing the interesting residues.
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